All In Biotech

Drug Trial Radar · NCT07095127

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

An Open-Label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants With Immune Thrombocytopenia

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Sep 30, 2025

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Nuvig Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with ITP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

  • NVG-2089Drug

    Study Treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate incidence, nature and severity of Treatment Emergent Adverse Events (TEAEs)Time frame: From enrollment to end of treatment Week 20
  2. Evaluate incidence, nature and severity of Serious Adverse Events (SAEs)Time frame: From enrollment to end of treatment Week 20

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.